Pituitary Stalk Interruption Syndrome (PSIS) Market to Reach USD 52.8 Million by 2034

Pune, India - December 2025 - The global Pituitary Stalk Interruption Syndrome (PSIS) Market, valued at USD 27.6 million in 2024, is projected to reach USD 52.8 million by 2034, growing at a 6.7% CAGR (2025-2034), according to Exactitude Consultancy. Improvements in MRI-based diagnosis, rising awareness among pediatric endocrinologists, and increased adoption of long-acting hormone therapies are supporting market expansion.

Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/72059

Market Summary
The PSIS Market is growing gradually as advancements in neuroimaging, endocrine diagnostics, and pediatric hormonal therapies improve early detection and long-term management of this rare congenital disorder. Pituitary Stalk Interruption Syndrome is characterized by the triad of interrupted pituitary stalk, absent/ectopic posterior pituitary, and anterior pituitary hypoplasia, leading to multiple hormone deficiencies such as GH, TSH, ACTH, LH, and FSH.

Treatment primarily involves lifelong hormone replacement therapy (HRT) tailored to each deficiency, including growth hormone therapy, adrenal insufficiency management, thyroid hormone replacement, and gonadotropin therapy. Increasing clinical recognition, improved neonatal screening, and wider access to recombinant growth hormone products contribute to steady market growth. North America and Europe dominate due to advanced endocrine care, while Asia-Pacific shows rising incidence detection through improved MRI access.

Key Takeaways
• 2024 Market Size: USD 27.6 Million
• 2034 Forecast: USD 52.8 Million
• CAGR: 6.7% (2025-2034)
• MRI advancements improving diagnosis accuracy
• Growth hormone therapy remains central to management
• Asia-Pacific expanding with improved pediatric endocrine services

Explore Full Report here:
https://exactitudeconsultancy.com/reports/72059/pituitary-stalk-interruption-syndrome-psis-market

Market Drivers
• Increased availability of high-resolution MRI for pituitary evaluation
• Growing clinical awareness of congenital hypopituitarism
• Advancements in recombinant & long-acting growth hormone formulations
• Wider adoption of lifelong hormone replacement therapies
• Rising access to endocrinology care in developing regions

Segmentation Snapshot
By Treatment Type
• Growth Hormone Therapy
• Thyroid Hormone Replacement
• Cortisol Replacement (Hydrocortisone)
• Gonadotropin Therapy
• Desmopressin (for select cases)
• Supportive & Metabolic Management

By Diagnosis Method
• MRI Imaging (Gold Standard)
• Hormonal Panel Testing
• Genetic Testing
• Clinical Neonatal Evaluation

By End User
• Hospitals
• Pediatric Endocrinology Centers
• Specialty Clinics
• Research Institutions

By Region
• North America (Largest Market)
• Europe
• Asia-Pacific (Fastest Growing)
• Latin America
• Middle East & Africa

Get Your Exclusive Offer with up to 10% Discount
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72059

Recent Developments
• Increased adoption of long-acting GH therapy improving patient compliance.
• Improvements in neonatal endocrine screening protocols.
• Research in genetic underpinnings of PSIS to improve targeted management.
• Enhanced pediatric MRI access enabling earlier detection in developing regions.

Expert Quote - Irfan Tamboli, Business Development Executive
"Greater clinical awareness and improved imaging technologies are helping diagnose PSIS earlier, enabling timely hormone replacement therapies that significantly improve long-term outcomes."

Conclusion
The Pituitary Stalk Interruption Syndrome Market is poised for steady growth through 2034 as diagnostic imaging advances, recombinant hormone therapies evolve, and pediatric endocrinology infrastructure improves globally. Companies offering long-acting hormonal formulations, advanced MRI tools, and genetic diagnostics will shape future market progress.

This report is also available in the following languages : Japanese (下垂体茎中断症候群(PSIS)市場), Korean (뇌하수체 줄기 중단 증후군(PSIS) 시장), Chinese (垂体柄中断综合征(PSIS)市场), French (Marché du syndrome d'interruption de la tige pituitaire (PSIS)), German (Markt für das Hypophysenstiel-Unterbrechungssyndrom (PSIS)), and Italian (Mercato della sindrome da interruzione del peduncolo pituitario (PSIS)), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/72059

Our More Reports:

Dravet Syndrome (DS) Market
https://exactitudeconsultancy.com/reports/72087/dravet-syndrome-ds-market

Generalized Myasthenia Gravis (gMG) Market
https://exactitudeconsultancy.com/reports/72089/generalized-myasthenia-gravis-gmg-market

Lennox Gastaut Syndrome Market
https://exactitudeconsultancy.com/reports/72091/lennox-gastaut-syndrome-market

Neuromyelitis optica spectrum disorder (NMOSD) Market
https://exactitudeconsultancy.com/reports/72093/neuromyelitis-optica-spectrum-disorder-nmosd-market

https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.

This release was published on openPR.